Intelligent Bio Solutions Inc.a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced plans for a major upgrade to its Intelligent Fingerprinting Drug Screening System. The system upgrade will support multiple languages spoken across North and South America, Europe, Asia Pacific and the Middle East, making the system accessible to over 4 billion speakers worldwide.
By introducing multilingual capabilities to its portable Drug Screening Reader, INBS is expanding access to the system and addressing the diverse needs of global organizations operating in multilingual environments. The update will enhance usability, ensuring greater efficiency in safety-critical industries such as construction, mining, manufacturing, transport, and logistics worldwide. This move aligns with the rapidly growing demand for workplace drug testing solutions, a market projected to reach approximately $8 billion globally by 20302.
“As we expand our global footprint, it is essential that our solutions are accessible and adaptable to meet the needs of an increasingly diverse customer base,” said Harry Simeonidis, President & CEO of Intelligent Bio Solutions. “This multilingual upgrade to our drug screening reader represents a significant step forward in our mission to deliver accessible testing solutions. Importantly, this update will open up opportunities for us to enter new international markets and customer segments, supporting revenue growth.”
INBS’ non-invasive Intelligent Fingerprinting Drug Testing Solution leverages innovative fingerprint sweat analysis to efficiently detect multiple substances of abuse simultaneously. The addition of multilingual capabilities aligns with INBS’ plans to scale its presence in key markets across the Americas, Europe, Asia, and the Middle East. The planned update supports INBS’ strategic international expansion by building on the Company’s recent FDA 510(k) submission in December 2024, its established presence in 19 countries, and its planned entry into the US market in 2025.
